This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rosetta Genomics Ltd (ROSG)

NASDAQ: Health Care

Company Income Statement
Dec 2015 Dec 2014 Dec 2013 Dec 2012
Sales 8.27M 1.33M 405.00K 201.00K
Cost of Sales 5.52M 1.01M 411.00K 258.00K
Gross Operating Profit 2.74M 316.00K -6.00K -57.00K
Selling, General, and Administrative Expenses 14.92M 12.34M 11.30M 6.96M
Research & Development 2.96M 1.93M 1.74M 1.25M
Operating Income before D & A (EBITDA) -15.13M -13.95M -13.05M -8.27M
Depreciation & Amortization 748.00K 299.00K 298.00K 1.82M
Interest Income 46.00K 0.00 146.00K 39.00K
Other Income - Net -1.45M 0.00 52.00K -2.15M
Special Income / Charges -155.00K 0.00 0.00 0.00
Total Income Before Interest Expenses (EBIT) -17.28M -14.25M -13.15M -12.20M
Interest Expense 48.00K 259.00K 21.00K 319.00K
Pre-Tax Income -17.33M -14.51M -13.17M -12.52M
Income Taxes 19.00K 15.00K 0.00 0.00
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations -17.34M -14.53M -13.17M -10.70M
Net Income From Discontinued Operations 0.00 0.00 273.00K 239.00K
Net Income From Total Operations -17.34M -14.53M -12.90M -10.46M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income -17.34M -14.53M -12.90M -10.46M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-17.34M -14.53M -13.17M -10.70M
Preferred Dividends
Net Income Available To Common -17.34M -14.53M -13.17M -10.70M
Basic EPS from Continuing Ops. -1.15 -1.29 -1.37 -2.40
Basic EPS from Discontinued Ops. 0.00 0.00 -0.03 0.05
Basic EPS from Total Operations -1.15 -1.29 -1.40 -2.35
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.06 0.00
Basic EPS, Total -1.15 -1.29 -1.34 -2.35
Basic Normalized Net Income/Share -1.15 -1.29 -1.37 -2.40
EPS fr Continuing Ops. -1.15 -1.29 -1.37 -2.40
EPS fr Discontinued Ops 0.00 0.00 -0.03 0.05
EPS fr Total Ops. -1.15 -1.29 -1.40 -2.35
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.06 0.00
EPS, Total -1.15 -1.29 -1.34 -2.35
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-1.15 -1.29 -1.37 -2.40
Dividends Paid per Share 0.00 0.00 0.00 0.00
ROSG News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

ROSG Rosetta Genomics Ltd

Chart of ROSG

Analysts Ratings for ROSG

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 4 4 4 4
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET ROSG ANALYST REPORT

ROSG Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs